Loading
Alzheimer Disease / Disease Models, Animal / Alzheimer's Disease · Journal article
Gut Microbes · December 29, 2025
Early or partial results. Treat as a signal, not a conclusion.
This mechanistic study identifies increased Blautia coccoides abundance in AD patients and demonstrates that B. coccoides supplementation exacerbates cognitive impairment and tau phosphorylation in P301s transgenic mice. The authors identify TMAO as a key microbial metabolite that binds HIF1α and promotes oxidative stress in vitro, proposing a novel pathway linking a specific gut bacterium to AD pathology.
Mixed-methods mechanistic study: human observational cohort, animal model supplementation trial, and in vitro functional analysis. 22 AD patients and controls; P301s transgenic mice; in vitro cell culture systems. Text truncated before full eligibility criteria and methods.. Intervention: Blautia coccoides supplementation in mice; TMAO exposure in cell culture; functional gene analysis and metabolomic profiling. Compared with: Healthy controls (human observational); vehicle or untreated controls in animal and cell studies (not detailed in provided text). China (Wenzhou Medical University affiliation).
Blautia coccoides abundance was increased in AD patients compared to healthy controls B. coccoides supplementation exacerbated cognitive impairment and tau phosphorylation in P301s mice TMAO identified as key B. coccoides-derived metabolite promoting tau phosphorylation
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work proposes a mechanistic rationale for targeting B. coccoides or TMAO as therapeutic strategies in AD, but the evidence remains preclinical. Clinical translation would require human intervention trials demonstrating that reducing B. coccoides abundance or TMAO levels improves cognitive outcomes or biomarkers.
Mechanistic study in animal models and cell cultures with observational human data; identifies a putative pathway but lacks clinical outcome validation or human intervention trials needed for stronger evidence.
As stated by the source record.
Quoted from the source exactly as published.
This work proposes a mechanistic rationale for targeting B. coccoides or TMAO as therapeutic strategies in AD, but the evidence remains preclinical. Clinical translation would require human intervention trials demonstrating that reducing B. coccoides abundance or TMAO levels improves cognitive outcomes or biomarkers.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
An increasing number of studies have shown that commensal gut microbes may be involved in the pathogenesis of Alzheimer's disease (AD). The influence of gut microbe-derived metabolites, such as trimethylamine N-oxide (TMAO), has attracted a lot of attention. However, the influence and pathways mediated by gut microbe-derived metabolites in the pathogenesis of AD remain uncertain. Here, we observed a significant increase in the abundance of Blautia coccoides in AD patients, which showed positive predictive value for serum p-Tau181 levels. Supplementation with B. coccoides could exacerbate cognitive impairment and Tau phosphorylation in P301s mice. We identified TMAO as a key B. coccoides-derived metabolite promoting Tau phosphorylation by functional gene analysis, metabolomic analysis and VIP analysis, and further demonstrated that it was able to promote oxidative stress of AD in vitro. Mechanistically, TMAO could bind to hypoxia-inducible factor 1 alpha (HIF1α) at 235-238 sites, which promoted oxidative stress through the inhibition of HIF1α signal, thereby aggravating AD pathology. This study elucidated the important role of B. coccoides-derived metabolite TMAO in exacerbating AD and provided new insights for gut microbe/metabolite-based therapeutic strategies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.